• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation.
CONCLUSIONS: Patients who had been treated with rivaroxaban may be a cost-effective alternative to warfarin for stroke prevention in Korean patients with AF. PMID: 30468041 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - November 25, 2018 Category: Cardiology Tags: Korean Circ J Source Type: research

Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer.
CONCLUSIONS: In AF patients with newly diagnosed cancer, NOACs showed lower incidences of ischemic stroke/SE, major bleeding, and all-cause death than warfarin, especially within 1 year after cancer diagnosis. PMID: 29671285 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - April 21, 2018 Category: Cardiology Tags: Korean Circ J Source Type: research

Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients.
Authors: Joung B Abstract Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation (AF). The results of the trials showed that all NOACs were at least non-inferior to warfarin in the prevention of stroke/thromboembolism and showed lower rates of intracranial bleeding than those associated with warfarin. However, the trials were designed differently, varied in the inclusion/exclusion criteria, and used either one dose or a low/high dose of the...
Source: Korean Circulation Journal - November 26, 2017 Category: Cardiology Tags: Korean Circ J Source Type: research

Impact of Anticoagulation Intensity in Korean Patients with Atrial Fibrillation: Is It Different from Western Population?
CONCLUSIONS: Mean INR 1.6-2.6 was better than mean INR 2.0-3.0 for the prevention of thromboembolism and major bleeding. However, INR 1.6-2.6 and TTR ≥70% had similar clinical outcomes to INR 2.0-3.0 and TTR ≥70% in Korean patients with non-valvular AF. PMID: 31642215 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - October 25, 2019 Category: Cardiology Tags: Korean Circ J Source Type: research